New prospects for cardiovascular gene therapy

Bibliography

• DENEFLE P, DUVERGER N, BRANELLEC D: Genetic thera-pies for vascular diseases and lipid disorders. Exp. Opin. Invest. Drugs (1995) 4 (11) :1129–1137.
   Google Scholar
• RADE JJ, SCHULICK AH, VIRMANI R, DICHEK DA: Local adenoviral-mediated expression of recombinant hi-rudin reduces neointima formation after arterial in-jury. Nature Med. (1996) 2(3):293–298.
   PubMed Web of Science ®Google Scholar
• This is the first report of local delivery of the potent thrombininhibitor hirudin to a site of arterial injury. Secretion of hi-rudin following in vivoAd-mediated gene delivery to injured rat carotid arteries resulted in a 35% reduction in neointima formation. The data support the notion that local thrombin activity contributes to the arterial response to injury and thus constitutes a novel target for cardiovascular gene therapy of restenosis.
   Google Scholar
• LEMARCHAND P, JONES M, YAMADA I, CRYSTAL RG: In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ. Res. (1993) 72 (5):1132–1138.
   PubMed Web of Science ®Google Scholar
• GUZMAN RJ, LEMARCHAND P, CRYSTAL RG, EPSTEIN SE, FINKEL T: Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation (1993) 88(6)2838–2848.
   Google Scholar
• GUZMAN RJ, HIRSCHOWITZ EA, BRODY SL et al.: In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA (1994) 91 (22) :10732–10736.
   PubMed Web of Science ®Google Scholar
• STEG PG, FELDMAN LJ, SCOAZEC JY et al.: Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation (1994) 90(4) :1648–1656.
   PubMed Web of Science ®Google Scholar
• FELDMAN LI STEG PG, ZHENG LP et al: Low-efficiency of percutaneous adenovirus-mediated arterial gene trans-fer in the atherosclerotic rabbit [see comments]. J. Clin. Invest. (1995) 95(6):2662–2671.
   PubMed Web of Science ®Google Scholar
• LANDAU C, PIRWITZ MJ, WILLARD MA et al.: Adenoviral mediated gene transfer to atherosclerotic arteries after balloon angioplasty. Am. Heart J. (1995) 129(6)1051–1057.
   Google Scholar
• GUZMAN RJ, LEMARCHAND P, CRYSTAL RG, EPSTEIN SE,FINKEL T: Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ. Res. (1993) 73 (6):1202–1207.
   PubMed Web of Science ®Google Scholar
• KASS-EISLER A, FALCK-PEDERSEN E, ALVIRA M et al: Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc. Natl. Acad. Sci. USA (1993) 90 (24) :11498–11502.
   PubMed Web of Science ®Google Scholar
• BARR E, CARROLL J, KALYNYCH AM et al.: Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther. (1994) 1 (0 :51–58.
   PubMedGoogle Scholar
• OHNO T, GORDON D, SAN H et al.: Gene therapy for vas-cular smooth muscle cell proliferation after arterial in-jury [see comments]. Science (1994) 265 (5173) 781–784.
   PubMed Web of Science ®Google Scholar
• CHANG MW, BARR E, SELTZER J et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene prod-uct. Science (1995) 267(5197):518–522.
   PubMed Web of Science ®Google Scholar
• YANG Y, ERTL HC, WILSON JM: MHC class I-restricted cy-totoxic T lymphocytes to viral antigens destroy hepato-cytes in mice infected with El-deleted recombinant adenoviruses. Immunity (1994) 1 (5) 433–442.
   PubMed Web of Science ®Google Scholar
• YANG Y, LI Q, ERTL HC, WILSON JM: Cellular and humo-ral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant ad-enoviruses. j Virol. (1995) 69(4) :2004–2015.
   PubMed Web of Science ®Google Scholar
• SCHULICK AH, NEWMAN KD, VIRMANI R, DICHEK DA: In vivo gene transfer into injured carotid arteries. Optimi-zation and evaluation of acute toxicity. Circulation (1995) 91 (9) :2407–2414.
   Google Scholar
• NEWMAN KD, DUNN PF, OWENS JAN et al: Adenovirus-mediated gene transfer into normal rabbit arteries re-sults in prolonged vascular cell activation, inflamma-tion, and neointimal hyperplasia. J. Clin. Invest. (1995) 96(6) 2955–2965.
   PubMed Web of Science ®Google Scholar
• SCHULICK AH, VASSALLI G, DUNN PF et al.: Established immunity precludes adenovirus-mediated gene trans-fer in rat carotid arteries. Potential for immunosup-pression and vector engineering to overcome barriers of immunity. J. Clin. Invest. (1997) 99 (2) :209–219.
   Google Scholar
• This paper provides an evaluation of the use of Ad vectors ina clinically relevant context, and underlines the host immune response issues hampering their use in the cardiovascular system.
   Google Scholar
• BRAMSON JL, GRAHAM FL, GAULDIE J: The use of adeno-viral vectors for gene therapy and gene transfer in vivo. Curr. Opin. Biotechnol (1995) 6(5):590–595.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT JF, YE X, DORANZ B, WILSON JM: Ablation of E2A in recombinant adenoviruses improves trans-gene persistence and decreases inflammatory re-sponse in mouse liver. Proc. Natl. Acad. Sci. USA (1994) 91(13)6196–6200.
   Google Scholar
• FANG B, WANG H, GORDON G et al: Lack of persistence of El-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocom-petent mice and hemophilia B dogs. Gene Ther. (1996) 3(3):217–222.
   PubMed Web of Science ®Google Scholar
• BETT AJ, HADDARA W, PREVEC L, GRAHAM FL: An effi-cient and flexible system for construction of adenovi-rus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA (1994) 91 (19) :8802–8806.
   PubMed Web of Science ®Google Scholar
• GAO GP, YANG Y, WILSON JM: Biology of adenovirus vectors with El and E4 deletions for liver- directed gene therapy. J. Virol. (1996) 70(12):8934–8943.
   PubMed Web of Science ®Google Scholar
• FISHER KJ, CHOI H, BURDA J, CHEN SJ, WILSON JM: Re-combinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology (1996) 217(1):11–22.
   PubMed Web of Science ®Google Scholar
• KOCHANEK S, CLEMENS PR, MITANI K et al: A new adeno-viral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA (1996) 93(12):5731–5736.
   PubMed Web of Science ®Google Scholar
• YEH P, DEDIEU JF, ORSINI C et al.: Efficient dual trans-complementation of adenovirus El and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J. Virol. (1996) 70(1):559–565.
   PubMed Web of Science ®Google Scholar
• ZHOU H, O'NEAL W, MORRAL N, BEAUDET AL: Develop-ment of a complementing cell line and a system for construction of adenovirus vectors with El and E2a de-leted. J. Virol. (1996) 70(l0):7030–7038.
   Google Scholar
• GNATENKO D, ARNOLD TE, ZOLOTUKHIN S et al.: Char-acterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vas-cular cells. J. Invest. Med. (1997) 45(2):87–98.
   PubMed Web of Science ®Google Scholar
• This paper describes gene transfer to HUVEC and to over90% of endothelial and SMC in rat carotid arteries using crude lysate preparations of AAV and rAAV vectors.
   Google Scholar
• ARNOLD TE, GNATENKO D, BAHOU WF: In vivo gene transfer into rat arterial walls with novel adeno- associ-ated virus vectors. J. Vasc. Surg. (1997) 25(2):347–355.
   PubMed Web of Science ®Google Scholar
• This paper is a extension of the work presented in [28] by thesame group of investigators. They show that the percentage of cells in the vessel wall that contained the transgene de-creased over time, but gene expression remained detectable for up to 1 month in tissue lysates prepared from the arteries.
   Google Scholar
• FISHER KJ, GAO GP, WEITZMAN MD et al.: Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. (1996) 70(0:520–532.
   PubMedGoogle Scholar
• FERRARI FK, SAMULSKI T, SHENK T, SAMULSKI RJ: Second-strand synthesis is a rate-limiting step for effi-cient transduction by recombinant adeno-associated virus vectors. J. Virol. (1996) 70(5):3227–3234.
   PubMed Web of Science ®Google Scholar
• LYNCH CM, HARA PS, LEONARD JC et al.: Adeno-associated virus vectors for vascular gene delivery. Circ. Res. (1997) 80(4):497–505.
   PubMed Web of Science ®Google Scholar
• This paper demonstrates rAAV-mediated transduction (i.e.,gene expression) in endothelial and SMC from a variety of species and in situ in the vessel wall of atherosclerotic cyno-molgus monkeys using purified vector. Interestingly, micro-vascular endothelial cells in the adventitia preferentially expressed the transgene and transduction was enhanced by balloon injury.
   Google Scholar
• ROLLING F, NONG Z, PISVIN S, COLLEN D: Adenoassociated virus-mediated gene transfer into rat carotid arteries. Gene Ther. (1997) 4(750:761.
   Google Scholar
• This paper describes transduction of medial and adventialcells in rat carotid arteries with higher efficiency transduction in injured vessels using purifed rAAV vector. Transgene ex-pression increased over time and persisted long-term as com-pared to Ad delivery.
   Google Scholar
• KAPLITT MG, XIAO X, SAMULSKI RJ et al.: Long-term gene transfer in porcine myocardium after coronary infu-sion of an adeno-associated virus vector. Ann. Thorac. Surg. (1996) 62 (6): 1669–1676 .
   PubMed Web of Science ®Google Scholar
• This paper demonstrated long-term wide spread transduc-tion of cardiac myocytes after infusion of rAAV vectors in porcine coronary arteries without apparent toxicity or inflam-mation.
   Google Scholar
• SIMONS M, EDELMAN ER, DEKEYSER JL, LANGER R, RO-SENBERG RD: Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 359(639067–70.
   Google Scholar
• BIRO S, FU YM, YU ZX, EPSTEIN SE: Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migra-tion. Proc. Natl. Acad. Sci. USA (1993) 90(2):654–658.
   PubMed Web of Science ®Google Scholar
• BENNETT MR, ANGLIN S, MCEWAN JR et al.: Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J. Clin. Invest. (1994) 93 (2) :820–828.
   PubMed Web of Science ®Google Scholar
• SHI Y, FARD A, GALEO A et al: Transcatheter delivery ofc-myc antisense oligomers reduces neointimal forma-tion in a porcine model of coronary artery balloon in-jury. Circulation (1994) 90(2)944–951.
   Google Scholar
• VILLA AE, GUZMAN LA, POPTIC EJ et al: Effects of an-tisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall in-jury. Circ. Res. (1995) 76(4):505–513.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, GIBBONS GH, ELLISON KE et al: Single in-traluminal delivery of antisense cdc2 kinase and prolif-erating- cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA (1993) 90(18):8474–8478.
   PubMed Web of Science ®Google Scholar
• MANN MJ, GIBBONS GH, TSAO PS et al.: Cell cycle inhibi-tion preserves endothelial function in genetically engi-neered rabbit vein grafts. J. Clin. Invest. (1997) 99 (6):1295–1301.
   PubMed Web of Science ®Google Scholar
• SPEIR E, MODALI R, HUANG ES et al.: Potential role of hu-man cytomegalovirus and p53 interaction in coronary restenosis [see comments]. Science (1994) 265(5170)391–394.
   Google Scholar
• MORISHITA R, GIBBONS GH, ELLISON KE et al: Intimalhyperplasia after vascular injury is inhibited by an-tisense cdk 2 kinase oligonucleotides. J. Clin. Invest. (1994) 93 (4) :1458–1464.
   PubMed Web of Science ®Google Scholar
• AUTIERI MV, YUE TL, FERSTEIN GZ, OHLSTEIN E: An-tisense oligonucleotides to the p65 subunit of NF-kB in-hibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem. Biophys. Res. Commun. (1995) 213(3):827–836.
   PubMed Web of Science ®Google Scholar
• YANG ZY, SIMARI RD, PERKINS ND et al: Role of the p21cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Sci. USA (1996) 93(15):7905–7910.
   PubMed Web of Science ®Google Scholar
• INDOLFI C, AVVEDIMENTO EV, RAPACCIUOLO A eta].: In-hibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo [see com-ments]. Nature Med. (1995) 1 (6) :541–545.
   Google Scholar
• WEIR L, CHEN D, PASTORE C, ISNER JM, WALSH K: Expres-sion of gax, a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the pro-liferative response to balloon injury. J. Biol. Chem. (1995) 270(105457–5461.
   Google Scholar
• MORISHITA R, GIBBONS GH, HORIUCHI M et al: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle prolifera-tion in vivo. Proc. Natl. Acad. Sci. USA (1995) 92(13):5855–5859.
   PubMed Web of Science ®Google Scholar
• VON DER LEYEN HE, GIBBONS GH, MORISHITA R et al: Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. USA (1995) 92(4):1137–1141.
   PubMed Web of Science ®Google Scholar
• TAKESHITA S, TSURUMI Y, COUFFINAHL T et al.: Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab. Invest. (1996) 75 (4):487–501.
   PubMed Web of Science ®Google Scholar
• ISNER JM, PIECZEK A, SCHAINFELD R et al: Clinical evi-dence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb [see com-ments]. Lancet (1996) 348 (9024) :370–374.
   PubMed Web of Science ®Google Scholar
• GIORDANO FJ, PING P, MCKIRNAN MD eta].: Intracoro-nary gene transfer of fibroblast growth factor-5 in-creases blood flow and contractile function in an ischemic region of the heart [see comments]. Nat. Med. (1996) 2(5)534–539.
   Google Scholar